| abstract |
IT REFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING: (A) APIXABAN PARTICLES (4,5,6,7-TETRAHYDRO-1- (4-METOXYPHENYL) -7-OXO-6- [4- (2-OXO-1- PIPERIDINYL) PHENYL] -1H-PYRAZOLO [3,4-C] PYRIDIN-3-CARBOXAMIDE) CRYSTALLINE OF N-1 FORM WITH AN AVERAGE PARTICLE SIZE OF 85 MICRONS; (B) A PHARMACEUTICALLY ACCEPTABLE THINNER; (C) A SURFACE ACTIVE AGENT SUCH AS SODIUM LAURYL SULPHATE. ALSO REFERRED TO A PROCEDURE FOR THE PREPARATION OF APIXABAN TABLETS. SUCH COMPOSITION HAS GREATER BIOAVAILABILITY AND IS USEFUL IN THE TREATMENT OF THROMBOEMBOLIC DISORDERS. |